PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.00
Ask: 46.00
Change: 0.50 (1.12%)
Spread: 2.00 (4.545%)
Open: 44.50
High: 45.00
Low: 44.50
Prev. Close: 44.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge Cognition revenue climbs despite swing to annual loss

Wed, 03rd May 2023 17:21

(Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it had a "transformative" 2022, as revenue climbed 25% against the previous year.

The Cambridge, England-based digital health products technology developer said revenue in 2022 rose to GBP12.6 million, up 25% from GBP10.1 million a year earlier. Services revenue grew by 16% in 2022 to GBP6.5 million, whilst Software revenue climbed 39% to GBP5.0 million.

However, the company swung to a pretax loss of GBP600,000 from a pretax profit of GBP300,000 year-on-year. It also swung to a loss per share of 1.3 pence, from an earnings per share of 1.4 pence.

The financial results for the year were tempered by a slightly slower-than-expected final quarter, as the company experienced delays and scope reduction associated with large orders, Cambridge Cognition explained. It added that market forecasts suggest that this is not representative of a long-term trend.

The company ended 2022 with a contracted order book of GBP17.6 million, which increased further to GBP19.1 million in January, following the acquisition of Winterlight Labs.

Cambridge Cognition bought Winterlight Labs for GBP7.0 million back in January.

Looking ahead, Cambridge Cognition said that its strong contracted order book provides "excellent" revenue visibility through 2023.

"2022 was a transformational year for Cambridge Cognition, marked by significant multi-year orders, sustained revenue growth, and the expansion of our core product set," said Chief Executive Officer Matthew Stork.

"Looking ahead, we remain committed to our objectives of driving revenue and profit growth by increasing our market share through offering the most innovative technology, supported by outstanding scientific evidence and a very experienced team, in the high-value market for CNS drug development."

Shares in Cambridge Cognition closed down 4.6% to 93.00 pence each.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 Feb 2022 12:40

Cambridge Cognition awarded contracts worth £2.1m

(Sharecast News) - Brain health technology company Cambridge Cognition has been awarded contracts worth £2.1m, it announced on Wednesday, to provide cognitive assessments, electronic diaries, and third-party hardware for two clinical trials in neurodegenerative disease.

Read more
2 Feb 2022 10:45

Cambridge Cognition jumps on GBP2.1 million clinical trial contract

Cambridge Cognition jumps on GBP2.1 million clinical trial contract

Read more
2 Feb 2022 10:32

AIM WINNERS & LOSERS: AFC gets Extreme E boost; Chamberlin raises cash

AIM WINNERS & LOSERS: AFC gets Extreme E boost; Chamberlin raises cash

Read more
27 Jan 2022 17:49

TRADING UPDATES: Petropavlovsk expects lower output; Keywords robust

TRADING UPDATES: Petropavlovsk expects lower output; Keywords robust

Read more
10 Jan 2022 12:44

Cambridge Cognition wins contracts for two clinical trials

(Sharecast News) - Brain health technology company Cambridge Cognition has been awarded contracts for two clinical trials by an unnamed "top 20" pharmaceutical company, it announced on Monday, to assess the pro-cognitive effects of a new drug in schizophrenia.

Read more
10 Jan 2022 12:19

Cambridge Cognition wins assessment contracts for schizophrenia drug

Cambridge Cognition wins assessment contracts for schizophrenia drug

Read more
16 Dec 2021 21:55

IN BRIEF: Cambridge Cognition wins second GBP500,000 contract

IN BRIEF: Cambridge Cognition wins second GBP500,000 contract

Read more
10 Dec 2021 15:03

TRADING UPDATES: Omega disputes repayment; BWA applies for licenses

TRADING UPDATES: Omega disputes repayment; BWA applies for licenses

Read more
2 Nov 2021 15:01

EXECUTIVE CHANGES: CFOs drop like flies; ex-IG CEO to chair Scotgold

EXECUTIVE CHANGES: CFOs drop like flies; ex-IG CEO to chair Scotgold

Read more
26 Oct 2021 17:39

TRADING UPDATES: East Star makes buy; Kromek wins USD17 million deal

TRADING UPDATES: East Star makes buy; Kromek wins USD17 million deal

Read more
26 Oct 2021 09:11

Cambridge Cognition secures contract for 'sizeable' schizophrenia trial

(Sharecast News) - Digital brain health technology company Cambridge Cognition has secured a contract for a further sizeable schizophrenia trial with an existing customer, it announced on Tuesday.

Read more
21 Sep 2021 11:54

TRADING UPDATES: Cambridge Cognition in profit; PensionBee loss widens

TRADING UPDATES: Cambridge Cognition in profit; PensionBee loss widens

Read more
14 Sep 2021 16:11

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
3 Aug 2021 12:03

TRADING UPDATES: UK housing market boosts Belvoir; IOG spuds Blythe

TRADING UPDATES: UK housing market boosts Belvoir; IOG spuds Blythe

Read more
3 Aug 2021 09:31

Cambridge Cognition turns in 'strong financial performance' in H1

(Sharecast News) - Software firm Cambridge Cognition said on Tuesday that it had put on a "strong financial performance" in the six months ended 30 June, with both revenue and sales growth during the period.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.